BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
Number Citing Articles
1 Alfakeeh K, Azar M, Alfadhel M, Abdullah AM, Aloudah N, Alsaad KO. Rare genetic variant in the CFB gene presenting as atypical hemolytic uremic syndrome and immune complex diffuse membranoproliferative glomerulonephritis, with crescents, successfully treated with eculizumab. Pediatr Nephrol 2017;32:885-91. [PMID: 28210841 DOI: 10.1007/s00467-016-3577-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
2 Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, Azaiez H, Black-Ziegelbein EA, Meyer NC, Kolbe DL, Li Y, Frees K, Schnieders MJ, Thomas C, Nester C, Smith RJ. High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies. J Am Soc Nephrol 2016;27:1245-53. [PMID: 26283675 DOI: 10.1681/ASN.2015040385] [Cited by in Crossref: 60] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
3 Lu S, Liu S, Wietelmann A, Kojonazarov B, Atzberger A, Tang C, Schermuly RT, Gröne HJ, Offermanns S. Developmental vascular remodeling defects and postnatal kidney failure in mice lacking Gpr116 (Adgrf5) and Eltd1 (Adgrl4). PLoS One 2017;12:e0183166. [PMID: 28806758 DOI: 10.1371/journal.pone.0183166] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
4 Duineveld C, Verhave JC, Berger SP, van de Kar NC, Wetzels JF. Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series. American Journal of Kidney Diseases 2017;70:770-7. [DOI: 10.1053/j.ajkd.2017.06.024] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
5 Ariceta G. Optimal duration of treatment with eculizumab in atypical hemolytic uremic syndrome (aHUS)-a question to be addressed in a scientific way. Pediatr Nephrol 2019;34:943-9. [PMID: 30693384 DOI: 10.1007/s00467-019-4192-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
6 Heesterbeek DAC, Angelier ML, Harrison RA, Rooijakkers SHM. Complement and Bacterial Infections: From Molecular Mechanisms to Therapeutic Applications. J Innate Immun 2018;10:455-64. [PMID: 30149378 DOI: 10.1159/000491439] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 12.3] [Reference Citation Analysis]
7 Lee JM, Park YS, Lee JH, Park SJ, Shin JI, Park YH, Yoo KH, Cho MH, Kim SY, Kim SH, Namgoong MK, Lee SJ, Lee JH, Cho HY, Han KH, Kang HG, Ha IS, Bae JS, Kim NK, Park WY, Cheong HI. Atypical hemolytic uremic syndrome: Korean pediatric series. Pediatr Int 2015;57:431-8. [PMID: 25443527 DOI: 10.1111/ped.12549] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
8 Saida K, Ogura M, Kano Y, Ishimori S, Yoshikawa T, Nagata H, Sato M, Kamei K, Ishikura K. Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection -is plasma exchange or eculizumab use necessary? BMC Nephrol 2018;19:365. [PMID: 30558570 DOI: 10.1186/s12882-018-1168-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Brocklebank V, Wong EK, Fielding R, Goodship TH, Kavanagh D. Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri.. Clin Kidney J 2014;7:286-8. [PMID: 24944786 DOI: 10.1093/ckj/sfu032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
10 Jepson RE, Cardwell JM, Cortellini S, Holm L, Stevens K, Walker D. Cutaneous and Renal Glomerular Vasculopathy: What Do We Know so Far? Vet Clin North Am Small Anim Pract 2019;49:745-62. [PMID: 30961997 DOI: 10.1016/j.cvsm.2019.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Bhatia D, Khandelwal P, Sinha A, Hari P, Cheong HI, Bagga A. Incomplete penetrance of CD46 mutation causing familial atypical hemolytic uremic syndrome. Pediatr Nephrol 2015;30:2215-20. [DOI: 10.1007/s00467-015-3189-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ueda Y, Miwa T, Ito D, Kim H, Sato S, Gullipalli D, Zhou L, Golla M, Song D, Dunaief JL, Palmer MB, Song WC. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation. Kidney Int 2019;96:67-79. [PMID: 30910380 DOI: 10.1016/j.kint.2019.01.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
13 Okuda Y, Ishikura K, Terano C, Harada R, Hamada R, Hataya H, Ogata K, Honda M. Irreversible severe kidney injury and anuria in a 3-month-old girl with atypical haemolytic uraemic syndrome under administration of eculizumab: An infant with eculizumab-resistant aHUS. Nephrology 2016;21:261-5. [DOI: 10.1111/nep.12582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Warwick A, Khandhadia S, Ennis S, Lotery A. Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation? J Clin Med 2014;3:1234-57. [PMID: 26237601 DOI: 10.3390/jcm3041234] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
15 Brocklebank V, Kavanagh D. Protecting the kidney from complement: atypical haemolytic uraemic syndrome. Clin Med (Lond) 2014;14 Suppl 6:s89-94. [PMID: 25468928 DOI: 10.7861/clinmedicine.14-6-s89] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Sheerin NS, Kavanagh D, Goodship TH, Johnson S. A national specialized service in England for atypical haemolytic uraemic syndrome-the first year's experience. QJM 2016;109:27-33. [PMID: 25899302 DOI: 10.1093/qjmed/hcv082] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
17 de Jong S, Volokhina EB, de Breuk A, Nilsson SC, de Jong EK, van der Kar NCAJ, Bakker B, Hoyng CB, van den Heuvel LP, Blom AM, den Hollander AI. Effect of rare coding variants in the CFI gene on Factor I expression levels. Hum Mol Genet 2020;29:2313-24. [PMID: 32510551 DOI: 10.1093/hmg/ddaa114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
18 Ellington N, Wolf MTF, Kasten J, Rakheja D. Omental Arteriopathy in Primary Atypical Hemolytic Uremic Syndrome. Int J Surg Pathol 2017;25:515-7. [PMID: 28381151 DOI: 10.1177/1066896917699703] [Reference Citation Analysis]
19 Liszewski MK, Atkinson JP. Complement regulators in human disease: lessons from modern genetics. J Intern Med 2015;277:294-305. [PMID: 25495259 DOI: 10.1111/joim.12338] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
20 Gediz F, Payzin BK, Ecemis S, Güler N, Yilmaz AF, Topcugil F, Berdeli A. Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey. Transfusion and Apheresis Science 2016;55:357-62. [DOI: 10.1016/j.transci.2016.09.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Kavanagh D, Yu Y, Schramm EC, Triebwasser M, Wagner EK, Raychaudhuri S, Daly MJ, Atkinson JP, Seddon JM. Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet 2015;24:3861-70. [PMID: 25788521 DOI: 10.1093/hmg/ddv091] [Cited by in Crossref: 21] [Cited by in F6Publishing: 45] [Article Influence: 3.0] [Reference Citation Analysis]
22 Zhang Y, Kremsdorf RA, Sperati CJ, Henriksen KJ, Mori M, Goodfellow RX, Pitcher GR, Benson CL, Borsa NG, Taylor RP, Nester CM, Smith RJH. Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome. Kidney Int 2020;98:1265-74. [PMID: 32540405 DOI: 10.1016/j.kint.2020.05.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
23 Brocklebank V, Kumar G, Howie AJ, Chandar J, Milford DV, Craze J, Evans J, Finlay E, Freundlich M, Gale DP, Inward C, Mraz M, Jones C, Wong W, Marks SD, Connolly J, Corner BM, Smith-Jackson K, Walsh PR, Marchbank KJ, Harris CL, Wilson V, Wong EKS, Malina M, Johnson S, Sheerin NS, Kavanagh D. Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy. Kidney Int 2020;97:1260-74. [PMID: 32386968 DOI: 10.1016/j.kint.2020.01.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
24 Trojnár E, Józsi M, Uray K, Csuka D, Szilágyi Á, Milosevic D, Stojanović VD, Spasojević B, Rusai K, Müller T, Arbeiter K, Kelen K, Szabó AJ, Reusz GS, Hyvärinen S, Jokiranta TS, Prohászka Z. Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome. Front Immunol 2017;8:302. [PMID: 28424685 DOI: 10.3389/fimmu.2017.00302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
25 Speth C, Rambach G, Würzner R, Lass-flörl C, Kozarcanin H, Hamad OA, Nilsson B, Ekdahl KN. Complement and platelets: Mutual interference in the immune network. Molecular Immunology 2015;67:108-18. [DOI: 10.1016/j.molimm.2015.03.244] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 5.4] [Reference Citation Analysis]
26 Blaum BS, Frank M, Walker RC, Neu U, Stehle T. Complement Factor H and Simian Virus 40 bind the GM1 ganglioside in distinct conformations. Glycobiology 2016;26:532-9. [PMID: 26715202 DOI: 10.1093/glycob/cwv170] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
27 Rezaei N, Bonilla FA, Seppänen M, de Vries E, Bousfiha AA, Puck J, Orange J. Introduction on Primary Immunodeficiency Diseases. In: Rezaei N, Aghamohammadi A, Notarangelo LD, editors. Primary Immunodeficiency Diseases. Berlin: Springer Berlin Heidelberg; 2017. pp. 1-81. [DOI: 10.1007/978-3-662-52909-6_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
28 Epand RM, So V, Jennings W, Khadka B, Gupta RS, Lemaire M. Diacylglycerol Kinase-ε: Properties and Biological Roles. Front Cell Dev Biol 2016;4:112. [PMID: 27803897 DOI: 10.3389/fcell.2016.00112] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
29 Werner U, Künstner A, Drenckhan M, Pries R, Bruchhage KL, Busch HS, Bachert C, Wollenberg B. Linking Complement C3 and B Cells in Nasal Polyposis. J Immunol Res 2020;2020:4832189. [PMID: 32724828 DOI: 10.1155/2020/4832189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Holm L, Walker D. Dealing with cutaneous and renal glomerular vasculopathy in dogs. In pract 2018;40:426-38. [DOI: 10.1136/inp.k4368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
31 Radhakrishnan ST, Ruban A, Uthayakumar AK, Cohen P, Levy J, Teare J. Haemolytic uraemic syndrome - a rare case report of bloody diarrhoea in adults. BMC Gastroenterol 2019;19:156. [PMID: 31462210 DOI: 10.1186/s12876-019-1071-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Zheng XL. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 2015;66:211-25. [PMID: 25587650 DOI: 10.1146/annurev-med-061813-013241] [Cited by in Crossref: 92] [Cited by in F6Publishing: 81] [Article Influence: 13.1] [Reference Citation Analysis]
33 Hevey R, Pouw RB, Harris C, Ricklin D. Sweet turning bitter: Carbohydrate sensing of complement in host defence and disease. Br J Pharmacol 2021;178:2802-22. [PMID: 33140840 DOI: 10.1111/bph.15307] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Tanriover B, Lakhia R, Shen YM, Sandikci B, Saxena R, MacConmara M, Soyombo AA, Rajora N, Hardy MA. Characteristics and Outcomes of Renal Transplant Recipients with Hemolytic Uremic Syndrome in the United States. Transplant Direct 2015;1:e41. [PMID: 26949736 DOI: 10.1097/TXD.0000000000000555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Ferluga J, Kouser L, Murugaiah V, Sim RB, Kishore U. Potential influences of complement factor H in autoimmune inflammatory and thrombotic disorders. Mol Immunol 2017;84:84-106. [PMID: 28216098 DOI: 10.1016/j.molimm.2017.01.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
36 Kavanagh D, Raman S, Sheerin NS. Management of hemolytic uremic syndrome. F1000Prime Rep 2014;6:119. [PMID: 25580273 DOI: 10.12703/P6-119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zhu Z, Chen H, Gill R, Wang J, Spitalewitz S, Gotlieb V. Diabetic ketoacidosis presenting with atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult: a case report. J Med Case Rep 2016;10:38. [PMID: 26911616 DOI: 10.1186/s13256-016-0825-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Krishnappa V, Gupta M, Elrifai M, Moftakhar B, Ensley MJ, Vachharajani TJ, Sethi SK, Raina R. Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens: Meta-Analysis of Atypical HUS Case Reports. Therapeutic Apheresis and Dialysis 2018;22:178-88. [DOI: 10.1111/1744-9987.12641] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
39 Imus PH, Tsai HL, DeZern AE, Jerde K, Swinnen LJ, Bolaños-Meade J, Luznik L, Fuchs EJ, Wagner-Johnston N, Huff CA, Gladstone DE, Ambinder RF, Gocke CB, Ali SA, Borrello IM, Varadhan R, Brodsky R, Jones RJ. Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant 2020;26:2306-10. [PMID: 32961372 DOI: 10.1016/j.bbmt.2020.09.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Nunius C, Büttner-Herold M, Bertz S, Schiffer M, Buchholz B. Isolated thrombotic microangiopathy of the small intestine in a patient with atypical hemolytic uremic syndrome - a case report. BMC Nephrol 2020;21:104. [PMID: 32204691 DOI: 10.1186/s12882-020-01766-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Brodszki N, Frazer-Abel A, Grumach AS, Kirschfink M, Litzman J, Perez E, Seppänen MRJ, Sullivan KE, Jolles S. European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management. J Clin Immunol 2020;40:576-91. [PMID: 32064578 DOI: 10.1007/s10875-020-00754-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
42 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 20.6] [Reference Citation Analysis]
43 Dekkers G, Brouwer MC, Jeremiasse J, Kamp A, Biggs RM, van Mierlo G, Lauder S, Katti S, Kuijpers TW, Rispens T, Jongerius I. Unraveling the Effect of a Potentiating Anti-Factor H Antibody on Atypical Hemolytic Uremic Syndrome-Associated Factor H Variants. J Immunol 2020;205:1778-86. [PMID: 32848031 DOI: 10.4049/jimmunol.2000368] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Breunig M, Lalama M, Rivard G, Kashiwagi D, Cornell L. Acute kidney injury in a patient with hemolytic anemia and thrombocytopenia. JAAPA 2016;29:1-4. [PMID: 27787280 DOI: 10.1097/01.JAA.0000496961.12367.e2] [Reference Citation Analysis]
45 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
46 Blatt AZ, Pathan S, Ferreira VP. Properdin: a tightly regulated critical inflammatory modulator. Immunol Rev 2016;274:172-90. [PMID: 27782331 DOI: 10.1111/imr.12466] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
47 Gaut JP, Jain S, Pfeifer JD, Vigh-Conrad KA, Corliss M, Sharma MK, Heusel JW, Cottrell CE. Routine use of clinical exome-based next-generation sequencing for evaluation of patients with thrombotic microangiopathies. Mod Pathol 2017;30:1739-47. [PMID: 28752844 DOI: 10.1038/modpathol.2017.90] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
48 Bally S, Fourcade J, Frémeaux-Bacchi V. Haemolytic uraemic syndrome associated with non shiga toxin-producing Escherichia coli bacteraemia: a case report. BMC Nephrol 2019;20:157. [PMID: 31064333 DOI: 10.1186/s12882-019-1357-3] [Reference Citation Analysis]
49 So S, Fischer E, Gangadharan Komala M, Bose B. Postpartum atypical hemolytic uremic syndrome: Evaluating thrombotic microangiopathy in the pregnant woman. Obstet Med 2021;14:105-8. [PMID: 34394720 DOI: 10.1177/1753495X20926043] [Reference Citation Analysis]
50 Brocklebank V, Johnson S, Sheerin TP, Marks SD, Gilbert RD, Tyerman K, Kinoshita M, Awan A, Kaur A, Webb N, Hegde S, Finlay E, Fitzpatrick M, Walsh PR, Wong EKS, Booth C, Kerecuk L, Salama AD, Almond M, Inward C, Goodship TH, Sheerin NS, Marchbank KJ, Kavanagh D. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland. Kidney Int 2017;92:1261-71. [PMID: 28750931 DOI: 10.1016/j.kint.2017.04.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
51 Bernabéu-Herrero ME, Jiménez-Alcázar M, Anter J, Pinto S, Sánchez Chinchilla D, Garrido S, López-Trascasa M, Rodríguez de Córdoba S, Sánchez-Corral P. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome. Mol Immunol 2015;67:276-86. [PMID: 26163426 DOI: 10.1016/j.molimm.2015.06.021] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
52 Thergaonkar RW, Narang A, Gurjar BS, Tiwari P, Puraswani M, Saini H, Sinha A, Varma B, Mukerji M, Hari P, Bagga A. Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations. Clin Exp Nephrol 2018;22:653-60. [PMID: 28939980 DOI: 10.1007/s10157-017-1478-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
53 Geerlings MJ, Volokhina EB, de Jong EK, van de Kar N, Pauper M, Hoyng CB, van den Heuvel LP, den Hollander AI. Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration. Clin Genet 2018;94:330-8. [PMID: 29888403 DOI: 10.1111/cge.13392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
54 Szarvas N, Szilágyi Á, Csuka D, Takács B, Rusai K, Müller T, Arbeiter K, Réti M, Haris Á, Wagner L, Török S, Kelen K, Szabó AJ, Reusz GS, Morgan BP, Prohászka Z. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Molecular Immunology 2016;71:10-22. [DOI: 10.1016/j.molimm.2016.01.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
55 Hyvärinen S, Meri S, Jokiranta TS. Disturbed sialic acid recognition on endothelial cells and platelets in complement attack causes atypical hemolytic uremic syndrome. Blood 2016;127:2701-10. [PMID: 27006390 DOI: 10.1182/blood-2015-11-680009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
56 Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship TH. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology 2016;221:715-8. [DOI: 10.1016/j.imbio.2015.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
57 Floege J, Mak RH, Molitoris BA, Remuzzi G, Ronco P. Nephrology research—the past, present and future. Nat Rev Nephrol 2015;11:677-87. [DOI: 10.1038/nrneph.2015.152] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
58 Basnayake BMDB, Wazil AWM, Nanayakkara N, Samarakoon SMDK, Senavirathne EMSK, Thangarajah BUEWDR, Karunasena N, Mahanama RMBSS. Atypical hemolytic uremic syndrome: a case report. J Med Case Rep 2020;14:11. [PMID: 31928535 DOI: 10.1186/s13256-019-2334-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Nadasdy T. Thrombotic microangiopathy in renal allografts: the diagnostic challenge. Curr Opin Organ Transplant. 2014;19:283-292. [PMID: 24811438 DOI: 10.1097/mot.0000000000000074] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 3.6] [Reference Citation Analysis]
60 Kamla CE, Grigorescu-Vlass M, Wassilowsky D, Fischereder M, Hagl C, Schönermarck U, Pichlmaier MA, Peterss S, Jóskowiak D. Thrombotic microangiopathy following aortic surgery with hypothermic circulatory arrest: a single-centre experience of an underestimated cause of acute renal failure. Interact Cardiovasc Thorac Surg 2021:ivab231. [PMID: 34414411 DOI: 10.1093/icvts/ivab231] [Reference Citation Analysis]
61 Labat-de-Hoz L, Alonso MA. The formin INF2 in disease: progress from 10 years of research. Cell Mol Life Sci 2020;77:4581-600. [PMID: 32451589 DOI: 10.1007/s00018-020-03550-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
62 Sharkey K, Beernink PT, Langley JM, Gantt S, Quach C, Dold C, Liu Q, Galvan M, Granoff DM. Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein. mSphere 2019;4:e00393-19. [PMID: 31270173 DOI: 10.1128/mSphere.00393-19] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
63 Pérez-Calatayud ÁA, Briones-Garduño JC, Álvarez-Goris Mdel P, Sánchez Zamora R, Torres Aguilar AA, Mendoza-Mórales RE. [Atipical uremic hemolityc syndrome in pregnancy]. Cir Cir 2016;84:344-9. [PMID: 27004941 DOI: 10.1016/j.circir.2016.02.001] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
64 Blaum BS, Hannan JP, Herbert AP, Kavanagh D, Uhrín D, Stehle T. Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat Chem Biol 2015;11:77-82. [PMID: 25402769 DOI: 10.1038/nchembio.1696] [Cited by in Crossref: 169] [Cited by in F6Publishing: 155] [Article Influence: 21.1] [Reference Citation Analysis]
65 Kavanagh D, Smith-Jackson K. Eculizumab in children with hemolytic uremic syndrome. Kidney Int 2016;89:537-8. [PMID: 26880449 DOI: 10.1016/j.kint.2015.12.039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Saida K, Fukuda T, Mizuno K, Ogura M, Kamei K, Ito S. Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up. Front Pediatr 2019;7:519. [PMID: 31921730 DOI: 10.3389/fped.2019.00519] [Reference Citation Analysis]
67 Wong EKS, Hallam TM, Brocklebank V, Walsh PR, Smith-Jackson K, Shuttleworth VG, Cox TE, Anderson HE, Barlow PN, Marchbank KJ, Harris CL, Kavanagh D. Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD. Front Immunol 2020;11:602284. [PMID: 33519811 DOI: 10.3389/fimmu.2020.602284] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
69 Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3:34-45. [PMID: 25343125 DOI: 10.5582/irdr.2014.01001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
70 Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res 2015;165:306-20. [PMID: 25468487 DOI: 10.1016/j.trsl.2014.10.010] [Cited by in Crossref: 58] [Cited by in F6Publishing: 45] [Article Influence: 7.3] [Reference Citation Analysis]
71 Vaughn JL, Moore JM, Cataland SR. Acute Systolic Heart Failure Associated with Complement-Mediated Hemolytic Uremic Syndrome. Case Rep Hematol 2015;2015:327980. [PMID: 26557394 DOI: 10.1155/2015/327980] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
72 Cadet B, Meshoyrer D, Kim Z. Atypical hemolytic uremic syndrome: when pregnancy leads to lifelong dialysis: a case report and literature review. Cardiovasc Endocrinol Metab 2021;10:225-30. [PMID: 34765894 DOI: 10.1097/XCE.0000000000000247] [Reference Citation Analysis]
73 Ferrara D, Seddon JM. Phenotypic Characterization of Complement Factor H R1210C Rare Genetic Variant in Age-Related Macular Degeneration. JAMA Ophthalmol 2015;133:785-91. [PMID: 25880396 DOI: 10.1001/jamaophthalmol.2015.0814] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
74 Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov 2015;14:857-77. [PMID: 26493766 DOI: 10.1038/nrd4657] [Cited by in Crossref: 227] [Cited by in F6Publishing: 210] [Article Influence: 32.4] [Reference Citation Analysis]
75 Trojnar E, Józsi M, Szabó Z, Réti M, Farkas P, Kelen K, Reusz GS, Szabó AJ, Garam N, Mikes B, Sinkovits G, Mező B, Csuka D, Prohászka Z. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies. Front Immunol 2019;10:240. [PMID: 30858847 DOI: 10.3389/fimmu.2019.00240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
76 Kim S, Park E, Min SI, Yi NJ, Ha J, Ha IS, Cheong HI, Kang HG. Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation. J Korean Med Sci 2018;33:e4. [PMID: 29215813 DOI: 10.3346/jkms.2018.33.e4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
77 Liszewski MK, Atkinson JP. Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections. Curr Opin Immunol 2021;72:126-34. [PMID: 34004375 DOI: 10.1016/j.coi.2021.04.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Kawaguchi K, Kawanishi K, Sato M, Itabashi M, Fujii A, Kanetsuna Y, Huchinoue S, Ohashi R, Koike J, Honda K, Nagashima Y, Nitta K. Atypical hemolytic uremic syndrome diagnosed four years after ABO-incompatible kidney transplantation. Nephrology (Carlton) 2015;20 Suppl 2:61-5. [PMID: 26031589 DOI: 10.1111/nep.12465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Sakari Jokiranta T, Viklicky O, Al Shorafa S, Coppo R, Gasteyger C, Macia M, Pankratenko T, Shenoy M, Soylemezoglu O, Tsimaratos M, Wetzels J, Haller H. Differential diagnosis of thrombotic microangiopathy in nephrology. BMC Nephrol 2017;18:324. [PMID: 29080561 DOI: 10.1186/s12882-017-0727-y] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
80 Schmidt CQ, Hipgrave Ederveen AL, Harder MJ, Wuhrer M, Stehle T, Blaum BS. Biophysical analysis of sialic acid recognition by the complement regulator Factor H. Glycobiology 2018;28:765-73. [PMID: 29982679 DOI: 10.1093/glycob/cwy061] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
81 Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods 2018;461:15-22. [PMID: 30031798 DOI: 10.1016/j.jim.2018.07.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
82 Turley AJ, Gathmann B, Bangs C, Bradbury M, Seneviratne S, Gonzalez-Granado LI, Hackett S, Kutukculer N, Alachkar H, Hambleton S, Ritterbusch H, Kralickova P, Marodi L, Seidel MG, Dueckers G, Roesler J, Huissoon A, Baxendale H, Litzman J, Arkwright PD. Spectrum and management of complement immunodeficiencies (excluding hereditary angioedema) across Europe. J Clin Immunol 2015;35:199-205. [PMID: 25663093 DOI: 10.1007/s10875-015-0137-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
83 Liszewski MK, Java A, Schramm EC, Atkinson JP. Complement Dysregulation and Disease: Insights from Contemporary Genetics. Annu Rev Pathol. 2017;12:25-52. [PMID: 27959629 DOI: 10.1146/annurev-pathol-012615-044145] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
84 Pouw RB, Gómez Delgado I, López Lera A, Rodríguez de Córdoba S, Wouters D, Kuijpers TW, Sánchez-Corral P. High Complement Factor H-Related (FHR)-3 Levels Are Associated With the Atypical Hemolytic-Uremic Syndrome-Risk Allele CFHR3*B. Front Immunol 2018;9:848. [PMID: 29740447 DOI: 10.3389/fimmu.2018.00848] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
85 Holm LP, Hawkins I, Robin C, Newton RJ, Jepson R, Stanzani G, McMahon LA, Pesavento P, Carr T, Cogan T, Couto CG, Cianciolo R, Walker DJ. Cutaneous and renal glomerular vasculopathy as a cause of acute kidney injury in dogs in the UK. Vet Rec 2015;176:384. [PMID: 25802439 DOI: 10.1136/vr.102892] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
86 Gleeson PJ, Wilson V, Cox TE, Sharma SD, Smith-Jackson K, Strain L, Lappin D, McHale T, Kavanagh D, Goodship TH. Chromosomal rearrangement-A rare cause of complement factor I associated atypical haemolytic uraemic syndrome. Immunobiology 2016;221:1124-30. [PMID: 27268256 DOI: 10.1016/j.imbio.2016.05.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
87 Smith JL, Gunther NW. Commentary: Campylobacter and Hemolytic Uremic Syndrome. Foodborne Pathog Dis 2019;16:90-3. [PMID: 30307748 DOI: 10.1089/fpd.2018.2513] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
89 Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation. J Am Soc Nephrol. 2015;26:209-219. [PMID: 24904082 DOI: 10.1681/asn.2013121339] [Cited by in Crossref: 59] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
90 Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited Kidney Complement Diseases. Clin J Am Soc Nephrol 2021;16:942-56. [PMID: 33536243 DOI: 10.2215/CJN.11830720] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Dowen F, Wood K, Brown AL, Palfrey J, Kavanagh D, Brocklebank V. Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential. Clin Kidney J 2017;10:490-3. [PMID: 28852487 DOI: 10.1093/ckj/sfx030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
92 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
93 Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology 2016;71:131-42. [DOI: 10.1016/j.molimm.2016.01.010] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
94 Volk AL, Hu FJ, Berglund MM, Nordling E, Strömberg P, Uhlen M, Rockberg J. Stratification of responders towards eculizumab using a structural epitope mapping strategy. Sci Rep 2016;6:31365. [PMID: 27509843 DOI: 10.1038/srep31365] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
95 Zheng L, Zhang D, Cao W, Song WC, Zheng XL. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy. Blood 2019;134:1095-105. [PMID: 31409673 DOI: 10.1182/blood.2019001040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
96 Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124:1715-1726. [PMID: 25037630 DOI: 10.1182/blood-2014-02-558296] [Cited by in Crossref: 189] [Cited by in F6Publishing: 171] [Article Influence: 23.6] [Reference Citation Analysis]
97 Kang E, Yoo SH, Oh D, Joo KW, Kim YS, Yoon SS, Kim I, Park S, Lee H, Koh Y. Clinical dissection of thrombotic microangiopathy. Ann Hematol 2017;96:1715-26. [PMID: 28752391 DOI: 10.1007/s00277-017-3063-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
98 Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P. Atypical aHUS: State of the art. Mol Immunol. 2015;67:31-42. [PMID: 25843230 DOI: 10.1016/j.molimm.2015.03.246] [Cited by in Crossref: 162] [Cited by in F6Publishing: 136] [Article Influence: 23.1] [Reference Citation Analysis]
99 Sperati CJ, Moliterno AR. Thrombotic Microangiopathy. Hematology/Oncology Clinics of North America 2015;29:541-59. [DOI: 10.1016/j.hoc.2015.02.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
100 Blaum BS. The lectin self of complement factor H. Current Opinion in Structural Biology 2017;44:111-8. [DOI: 10.1016/j.sbi.2017.01.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
101 Deghmane AE, Taha MK. Invasive Bacterial Infections in Subjects with Genetic and Acquired Susceptibility and Impacts on Recommendations for Vaccination: A Narrative Review. Microorganisms 2021;9:467. [PMID: 33668334 DOI: 10.3390/microorganisms9030467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis 2014;73:1601-6. [PMID: 24845390 DOI: 10.1136/annrheumdis-2014-205287] [Cited by in Crossref: 138] [Cited by in F6Publishing: 124] [Article Influence: 17.3] [Reference Citation Analysis]
103 Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51. [PMID: 27989322 DOI: 10.1016/j.kint.2016.10.005] [Cited by in Crossref: 256] [Cited by in F6Publishing: 226] [Article Influence: 42.7] [Reference Citation Analysis]
104 Grigorescu M, Kamla CE, Wassilowsky D, Joskowiak D, Peterss S, Kemmner S, Pichlmaier M, Hagl C, Fischereder M, Schönermarck U. Severe Acute Kidney Injury in Cardiovascular Surgery: Thrombotic Microangiopathy as a Differential Diagnosis to Ischemia Reperfusion Injury. A Retrospective Study. J Clin Med 2020;9:E2900. [PMID: 32911781 DOI: 10.3390/jcm9092900] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Rodriguez E, Rallapalli PM, Osborne AJ, Perkins SJ. New functional and structural insights from updated mutational databases for complement factor H, Factor I, membrane cofactor protein and C3. Biosci Rep 2014;34:e00146. [PMID: 25188723 DOI: 10.1042/BSR20140117] [Cited by in Crossref: 47] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
106 Challis RC, Araujo GS, Wong EK, Anderson HE, Awan A, Dorman AM, Waldron M, Wilson V, Brocklebank V, Strain L. A De Novo Deletion in the Regulators of Complement Activation Cluster Producing a Hybrid Complement Factor H/Complement Factor H-Related 3 Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol. 2016;27:1617-1624. [PMID: 26490391 DOI: 10.1681/asn.2015010100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
107 van Beek AE, Kamp A, Kruithof S, Nieuwenhuys EJ, Wouters D, Jongerius I, Rispens T, Kuijpers TW, Gelderman KA. Reference Intervals of Factor H and Factor H-Related Proteins in Healthy Children. Front Immunol 2018;9:1727. [PMID: 30116238 DOI: 10.3389/fimmu.2018.01727] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
108 Sexton DJ, Reule S, Solid CA, Chen SC, Collins AJ, Foley RN. End-stage renal disease from hemolytic uremic syndrome in the United States, 1995-2010. Hemodial Int 2015;19:521-30. [PMID: 25689876 DOI: 10.1111/hdi.12281] [Reference Citation Analysis]
109 Prohászka Z, Nilsson B, Frazer-Abel A, Kirschfink M. Complement analysis 2016: Clinical indications, laboratory diagnostics and quality control. Immunobiology 2016;221:1247-58. [PMID: 27475991 DOI: 10.1016/j.imbio.2016.06.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
110 Challis RC, Ring T, Xu Y, Wong EK, Flossmann O, Roberts IS, Ahmed S, Wetherall M, Salkus G, Brocklebank V, Fester J, Strain L, Wilson V, Wood KM, Marchbank KJ, Santibanez-Koref M, Goodship TH, Kavanagh D. Thrombotic Microangiopathy in Inverted Formin 2-Mediated Renal Disease. J Am Soc Nephrol 2017;28:1084-91. [PMID: 27974406 DOI: 10.1681/ASN.2015101189] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
111 Kozlovskaya NL, Korotchaeva YV, Bobrova LA. Adverse outcomes in obstetric-atypical haemolytic uraemic syndrome: a case series analysis. J Matern Fetal Neonatal Med 2019;32:2853-9. [PMID: 29606012 DOI: 10.1080/14767058.2018.1450381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
112 Nagarajah S, Tepel M, Nielsen C, Assing K, Palarasah Y, Andersen LLT, Lange LB, Bistrup C. Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report. BMC Nephrol 2019;20:307. [PMID: 31390992 DOI: 10.1186/s12882-019-1469-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
113 Liszewski MK, Atkinson JP. Complement regulator CD46: genetic variants and disease associations. Hum Genomics 2015;9:7. [PMID: 26054645 DOI: 10.1186/s40246-015-0029-z] [Cited by in Crossref: 61] [Cited by in F6Publishing: 48] [Article Influence: 8.7] [Reference Citation Analysis]
114 Matsukuma E, Imamura A, Iwata Y, Takeuchi T, Yoshida Y, Fujimura Y, Fan X, Miyata T, Kuwahara T. Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation. Case Rep Nephrol 2014;2014:784943. [PMID: 25431709 DOI: 10.1155/2014/784943] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
115 Roberts D, Siegman I, Andeen N, Woodland D, Deloughery T, Rueda J, Olyaei A, Rehman S, Norman D, Lockridge J. De novo thrombotic microangiopathy in two kidney transplant recipients from the same deceased donor: A case series. Clin Transplant 2020;34:e13885. [PMID: 32314417 DOI: 10.1111/ctr.13885] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Fujisawa M, Yasumoto A, Kato H, Sugawara Y, Yoshida Y, Yatomi Y, Nangaku M. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function. Br J Haematol 2020;189:182-6. [PMID: 31879952 DOI: 10.1111/bjh.16297] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
117 Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, Takanami E, Meyer NC, Frees K, Thomas CP, Nester C, Smith RJH. Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:2809-19. [PMID: 30377230 DOI: 10.1681/ASN.2018070759] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
118 Clark WF, Huang SS, Walsh MW, Farah M, Hildebrand AM, Sontrop JM. Plasmapheresis for the treatment of kidney diseases. Kidney International 2016;90:974-84. [DOI: 10.1016/j.kint.2016.06.009] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 5.2] [Reference Citation Analysis]
119 Haydock L, Garneau AP, Tremblay L, Yen HY, Gao H, Harrisson R, Isenring P. Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy. J Mol Med (Berl) 2021. [PMID: 34714369 DOI: 10.1007/s00109-021-02102-1] [Reference Citation Analysis]
120 Gallan AJ, Chang A. A New Paradigm for Renal Thrombotic Microangiopathy. Semin Diagn Pathol 2020;37:121-6. [PMID: 32085935 DOI: 10.1053/j.semdp.2020.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
121 Lee H, Kang E, Kang HG, Kim YH, Kim JS, Kim HJ, Moon KC, Ban TH, Oh SW, Jo SK, Cho H, Choi BS, Hong J, Cheong HI, Oh D. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35:25-40. [PMID: 31935318 DOI: 10.3904/kjim.2019.388] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
122 Jlajla H, Dehman F, Jallouli M, Khedher R, Ayadi I, Zerzeri Y, Laadhar L, Sfar I, Mahfoudh A, Gorgi Y, Cheour E, Zouaghi K, Gargah T, Kallel Sellami M. Molecular basis of complement factor I deficiency in Tunisian atypical haemolytic and uraemic syndrome patients. Nephrology (Carlton) 2019;24:357-64. [PMID: 29292855 DOI: 10.1111/nep.13217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
123 Khandelwal P, Birla S, Bhatia D, Puraswani M, Saini H, Sinha A, Hari P, Sharma A, Bagga A. Mutations in membrane cofactor protein (CD46) gene in Indian children with hemolytic uremic syndrome. Clin Kidney J 2018;11:198-203. [PMID: 29644059 DOI: 10.1093/ckj/sfx078] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
124 Vaught AJ, Braunstein E, Chaturvedi S, Blakemore K, Brodsky RA. A review of the alternative pathway of complement and its relation to HELLP syndrome: is it time to consider HELLP syndrome a disease of the alternative pathway. J Matern Fetal Neonatal Med 2020;:1-9. [PMID: 32338085 DOI: 10.1080/14767058.2020.1755650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
125 Wong EKS, Kavanagh D. Diseases of complement dysregulation-an overview. Semin Immunopathol 2018;40:49-64. [PMID: 29327071 DOI: 10.1007/s00281-017-0663-8] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
126 Ipe TS, Lim J, Reyes MA, Ero M, Leveque C, Lewis B, Kain J. An extremely rare splice site mutation in the gene encoding complement factor I in a patient with atypical hemolytic uremic syndrome. J Clin Apher 2017;32:584-8. [PMID: 28455885 DOI: 10.1002/jca.21549] [Reference Citation Analysis]
127 Phillips EH, Westwood JP, Brocklebank V, Wong EK, Tellez JO, Marchbank KJ, McGuckin S, Gale DP, Connolly J, Goodship TH, Kavanagh D, Scully MA. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost 2016;14:175-85. [PMID: 26559391 DOI: 10.1111/jth.13189] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
128 Smith-Jackson K, Yang Y, Denton H, Pappworth IY, Cooke K, Barlow PN, Atkinson JP, Liszewski MK, Pickering MC, Kavanagh D, Cook HT, Marchbank KJ. Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice. J Clin Invest 2019;129:1061-75. [PMID: 30714990 DOI: 10.1172/JCI99296] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
129 Willows J, Brown M, Sheerin NS. The role of complement in kidney disease. Clin Med (Lond) 2020;20:156-60. [PMID: 32188650 DOI: 10.7861/clinmed.2019-0452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
130 Pepper RJ, Trompeter RS. The causes and consequences of paediatric kidney disease on adult nephrology care. Pediatr Nephrol 2021. [PMID: 34389906 DOI: 10.1007/s00467-021-05182-w] [Reference Citation Analysis]
131 Mathern DR, Heeger PS. Molecules Great and Small: The Complement System. Clin J Am Soc Nephrol 2015;10:1636-50. [PMID: 25568220 DOI: 10.2215/CJN.06230614] [Cited by in Crossref: 126] [Cited by in F6Publishing: 71] [Article Influence: 18.0] [Reference Citation Analysis]
132 Abbas F, El Kossi M, Kim JJ, Sharma A, Halawa A. Thrombotic microangiopathy after renal transplantation: Current insights in de novo and recurrent disease. World J Transplantation 2018; 8(5): 122-141 [PMID: 30211021 DOI: 10.5500/wjt.v8.i5.122] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 8] [Article Influence: 4.8] [Reference Citation Analysis]
133 Tseng MH, Tsai JD, Tsai IJ, Huang SM, Huang JL, Fan WL, Lee HJ, Wu TW, Lin SH. Whole-exome sequencing detects mutations in pediatric patients with atypical hemolytic uremic syndrome in Taiwan. Clin Chim Acta 2019;494:143-50. [PMID: 30905589 DOI: 10.1016/j.cca.2019.03.1623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
134 Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child 2018;103:285-91. [PMID: 28899876 DOI: 10.1136/archdischild-2016-311377] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
135 Zewde N, Gorham RD Jr, Dorado A, Morikis D. Quantitative Modeling of the Alternative Pathway of the Complement System. PLoS One 2016;11:e0152337. [PMID: 27031863 DOI: 10.1371/journal.pone.0152337] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
136 Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O. Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol 2015;30:783-9. [DOI: 10.1007/s00467-014-3003-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
137 Mohlin FC, Nilsson SC, Levart TK, Golubovic E, Rusai K, Müller-Sacherer T, Arbeiter K, Pállinger É, Szarvas N, Csuka D, Szilágyi Á, Villoutreix BO, Prohászka Z, Blom AM. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients. Mol Immunol 2015;65:367-76. [PMID: 25733390 DOI: 10.1016/j.molimm.2015.02.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
138 Xue X, Wu J, Ricklin D, Forneris F, Di Crescenzio P, Schmidt CQ, Granneman J, Sharp TH, Lambris JD, Gros P. Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses. Nat Struct Mol Biol 2017;24:643-51. [PMID: 28671664 DOI: 10.1038/nsmb.3427] [Cited by in Crossref: 59] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]
139 Maugeri A, Barchitta M, Mazzone MG, Giuliano F, Agodi A. Complement System and Age-Related Macular Degeneration: Implications of Gene-Environment Interaction for Preventive and Personalized Medicine. Biomed Res Int 2018;2018:7532507. [PMID: 30225264 DOI: 10.1155/2018/7532507] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
140 Kerr H, Wong E, Makou E, Yang Y, Marchbank K, Kavanagh D, Richards A, Herbert AP, Barlow PN. Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation. J Biol Chem 2017;292:13345-60. [PMID: 28637873 DOI: 10.1074/jbc.M117.795088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 3.4] [Reference Citation Analysis]
141 Frimat M, Boudhabhay I, Roumenina LT. Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit. Toxins (Basel) 2019;11:E660. [PMID: 31766155 DOI: 10.3390/toxins11110660] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
142 Bowen EE, Coward RJ. Advances in our understanding of the pathogenesis of hemolytic uremic syndromes. Am J Physiol Renal Physiol. 2018;314:F454-F461. [PMID: 29167171 DOI: 10.1152/ajprenal.00376.2017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
143 Józsi M, Reuter S, Nozal P, López-trascasa M, Sánchez-corral P, Prohászka Z, Uzonyi B. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunology Letters 2014;160:163-71. [DOI: 10.1016/j.imlet.2014.01.014] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
144 Andries G, Karass M, Yandrapalli S, Linder K, Liu D, Nelson J, Pawar R, Chugh S. Atypical hemolytic uremic syndrome in first trimester pregnancy successfully treated with eculizumab. Exp Hematol Oncol 2017;6:4. [PMID: 28101432 DOI: 10.1186/s40164-017-0064-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
145 De Luca C, Colangelo AM, Alberghina L, Papa M. Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. Front Cell Neurosci 2018;12:459. [PMID: 30534057 DOI: 10.3389/fncel.2018.00459] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
146 Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med 2017;281:123-48. [DOI: 10.1111/joim.12546] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 12.0] [Reference Citation Analysis]
147 Nagar VS, Chaterjee R, Sood A, Sajjan B, Kaushik A, Vyahalkar SV. Complements Spurned: Our Experience with Atypical Hemolytic Uremic Syndrome. Indian J Crit Care Med 2017;21:102-4. [PMID: 28250608 DOI: 10.4103/ijccm.IJCCM_341_16] [Reference Citation Analysis]
148 Azoulay E, Knoebl P, Garnacho-Montero J, Rusinova K, Galstian G, Eggimann P, Abroug F, Benoit D, von Bergwelt-Baildon M, Wendon J, Scully M. Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest 2017;152:424-34. [PMID: 28442312 DOI: 10.1016/j.chest.2017.03.055] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
149 Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep 2021;6:11-23. [PMID: 33102952 DOI: 10.1016/j.ekir.2020.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
150 González DP, Iglicki M, Svetitsky S, Bar-On Y, Habot-Wilner Z, Zur D. Occlusive retinal vasculopathy with macular branch retinal artery occlusion as a leading sign of atypical hemolytic uremic syndrome - a case report. BMC Ophthalmol 2021;21:65. [PMID: 33516177 DOI: 10.1186/s12886-021-01820-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Kerboua KE, Haiba F, Batouche D. C3:CH50 ratio as a proposed composite marker for eculizumab monitoring in atypical hemolytic uremic syndrome: Preliminary results. Journal of Immunoassay and Immunochemistry 2017;38:178-89. [DOI: 10.1080/15321819.2016.1234485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
152 Watson R, Wearmouth E, McLoughlin AC, Jackson A, Ward S, Bertram P, Bennaceur K, Barker CE, Pappworth IY, Kavanagh D, Lea SM, Atkinson JP, Goodship TH, Marchbank KJ. Autoantibodies to CD59, CD55, CD46 or CD35 are not associated with atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2015;63:287-96. [PMID: 25150608 DOI: 10.1016/j.molimm.2014.07.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
153 Knoop M, Haller H, Menne J. [Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment]. Internist (Berl) 2018;59:799-804. [PMID: 29995248 DOI: 10.1007/s00108-018-0455-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
154 Calvaruso L, Naticchia A, Ferraro PM, Vischini G, Costanzi S. Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report. Case Rep Nephrol 2019;2019:9264824. [PMID: 31360562 DOI: 10.1155/2019/9264824] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Ren Z, Perkins SJ, Love-Gregory L, Atkinson JP, Java A. Clinicopathologic Implications of Complement Genetic Variants in Kidney Transplantation. Front Med (Lausanne) 2021;8:775280. [PMID: 34912830 DOI: 10.3389/fmed.2021.775280] [Reference Citation Analysis]
156 Khandelwal P, Thomas CC, Rathi BS, Hari P, Tiwari AN, Sinha A, Bagga A. Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety. J Clin Apher 2019;34:555-62. [PMID: 31173399 DOI: 10.1002/jca.21711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
157 Blatt AZ, Saggu G, Cortes C, Herbert AP, Kavanagh D, Ricklin D, Lambris JD, Ferreira VP. Factor H C-Terminal Domains Are Critical for Regulation of Platelet/Granulocyte Aggregate Formation. Front Immunol 2017;8:1586. [PMID: 29218045 DOI: 10.3389/fimmu.2017.01586] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
158 Feitz WJC, van de Kar NCAJ, Orth-Höller D, van den Heuvel LPJW, Licht C. The genetics of atypical hemolytic uremic syndrome. Med Genet 2018;30:400-9. [PMID: 30930551 DOI: 10.1007/s11825-018-0216-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
159 Jalal D, Renner B, Laskowski J, Stites E, Cooper J, Valente K, You Z, Perrenoud L, Le Quintrec M, Muhamed I, Christians U, Klawitter J, Lindorfer MA, Taylor RP, Holers VM, Thurman JM. Endothelial Microparticles and Systemic Complement Activation in Patients With Chronic Kidney Disease. J Am Heart Assoc 2018;7:e007818. [PMID: 30006493 DOI: 10.1161/JAHA.117.007818] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
160 Sahutoglu T, Basturk T, Sakaci T, Koc Y, Ahbap E, Sevinc M, Kara E, Akgol C, Caglayan FB, Unsal A, Daha MR. Can eculizumab be discontinued in aHUS?: Case report and review of the literature. Medicine (Baltimore) 2016;95:e4330. [PMID: 27495036 DOI: 10.1097/MD.0000000000004330] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.4] [Reference Citation Analysis]
161 Sevinc M, Basturk T, Sahutoglu T, Sakaci T, Koc Y, Ahbap E, Akgol C, Kara E, Brocklebank V, Goodship TH, Kavanagh D, Unsal A. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report. J Med Case Rep 2015;9:92. [PMID: 25925370 DOI: 10.1186/s13256-015-0575-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
162 Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci 2016;31:1516-28. [PMID: 27550478 DOI: 10.3346/jkms.2016.31.10.1516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]